Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Tract Infections | 2 | 2024 | 341 | 1.360 |
Why?
|
| Vaccines | 2 | 2022 | 396 | 1.100 |
Why?
|
| Antiviral Agents | 8 | 2023 | 1261 | 1.090 |
Why?
|
| Influenza, Human | 5 | 2018 | 762 | 1.080 |
Why?
|
| Nitrofurantoin | 1 | 2024 | 11 | 0.950 |
Why?
|
| Hepatitis C, Chronic | 5 | 2024 | 470 | 0.870 |
Why?
|
| Adenosine | 1 | 2024 | 297 | 0.790 |
Why?
|
| Sofosbuvir | 2 | 2022 | 24 | 0.700 |
Why?
|
| Neoplasms | 20 | 2024 | 15891 | 0.670 |
Why?
|
| Influenza Vaccines | 2 | 2014 | 492 | 0.660 |
Why?
|
| Hepatitis C | 6 | 2024 | 550 | 0.640 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 3177 | 0.570 |
Why?
|
| Intraabdominal Infections | 1 | 2015 | 4 | 0.520 |
Why?
|
| West Nile Fever | 4 | 2004 | 158 | 0.510 |
Why?
|
| Anus Diseases | 1 | 2015 | 29 | 0.500 |
Why?
|
| Neutropenia | 4 | 2015 | 1001 | 0.500 |
Why?
|
| Demyelinating Diseases | 1 | 2015 | 81 | 0.490 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 196 | 0.410 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2024 | 499 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 2640 | 0.390 |
Why?
|
| Multiple Sclerosis | 1 | 2015 | 373 | 0.390 |
Why?
|
| West Nile virus | 4 | 2004 | 132 | 0.370 |
Why?
|
| Vaccination | 2 | 2015 | 1155 | 0.360 |
Why?
|
| Hepacivirus | 7 | 2024 | 423 | 0.340 |
Why?
|
| Referral and Consultation | 1 | 2013 | 936 | 0.290 |
Why?
|
| Papillomavirus Infections | 1 | 2015 | 1016 | 0.270 |
Why?
|
| Sustained Virologic Response | 3 | 2023 | 63 | 0.270 |
Why?
|
| Humans | 46 | 2024 | 270896 | 0.260 |
Why?
|
| Bacteremia | 4 | 2015 | 721 | 0.260 |
Why?
|
| HIV Infections | 4 | 2024 | 2154 | 0.260 |
Why?
|
| Acenaphthenes | 1 | 2024 | 7 | 0.240 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2024 | 12 | 0.240 |
Why?
|
| Culex | 1 | 2004 | 34 | 0.240 |
Why?
|
| Medical Oncology | 1 | 2013 | 1461 | 0.240 |
Why?
|
| Mosquito Control | 1 | 2004 | 34 | 0.240 |
Why?
|
| Tertiary Care Centers | 2 | 2024 | 419 | 0.230 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2004 | 86 | 0.220 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 153 | 0.220 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2023 | 68 | 0.210 |
Why?
|
| Drug Combinations | 1 | 2024 | 635 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 559 | 0.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 1067 | 0.190 |
Why?
|
| Pandemics | 4 | 2023 | 1594 | 0.190 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 95 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 2218 | 0.180 |
Why?
|
| Practice Patterns, Dentists' | 1 | 2020 | 6 | 0.180 |
Why?
|
| Middle Aged | 20 | 2024 | 90230 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2023 | 211 | 0.180 |
Why?
|
| Antifungal Agents | 2 | 2017 | 875 | 0.180 |
Why?
|
| Interferons | 2 | 2019 | 299 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2024 | 2162 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 59 | 0.170 |
Why?
|
| Catheter-Related Infections | 3 | 2017 | 276 | 0.170 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 215 | 0.170 |
Why?
|
| Female | 24 | 2024 | 148810 | 0.170 |
Why?
|
| Mass Screening | 3 | 2024 | 1548 | 0.170 |
Why?
|
| HIV-1 | 1 | 2024 | 637 | 0.170 |
Why?
|
| Communicable Diseases | 1 | 2022 | 209 | 0.170 |
Why?
|
| Simeprevir | 1 | 2019 | 9 | 0.170 |
Why?
|
| Immunity | 1 | 2021 | 356 | 0.170 |
Why?
|
| Fluorenes | 1 | 2019 | 19 | 0.160 |
Why?
|
| Saliva | 1 | 2020 | 238 | 0.160 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 700 | 0.160 |
Why?
|
| Carbamates | 1 | 2019 | 81 | 0.160 |
Why?
|
| Pyrrolidines | 1 | 2019 | 113 | 0.160 |
Why?
|
| Valine | 1 | 2019 | 180 | 0.160 |
Why?
|
| Double-Blind Method | 1 | 2024 | 2585 | 0.160 |
Why?
|
| Occupational Exposure | 1 | 2020 | 248 | 0.150 |
Why?
|
| Social Media | 1 | 2022 | 208 | 0.150 |
Why?
|
| Ribavirin | 1 | 2019 | 177 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2024 | 33709 | 0.150 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 126 | 0.150 |
Why?
|
| Adult | 13 | 2024 | 81883 | 0.150 |
Why?
|
| Male | 22 | 2024 | 128437 | 0.140 |
Why?
|
| Nitroglycerin | 1 | 2017 | 45 | 0.140 |
Why?
|
| Nucleic Acids | 1 | 2017 | 44 | 0.140 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 54 | 0.140 |
Why?
|
| Central Venous Catheters | 1 | 2017 | 100 | 0.130 |
Why?
|
| HIV | 1 | 2017 | 236 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2019 | 437 | 0.130 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 4804 | 0.130 |
Why?
|
| Mannans | 1 | 2015 | 31 | 0.130 |
Why?
|
| beta-Glucans | 1 | 2015 | 35 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 655 | 0.120 |
Why?
|
| Hematologic Neoplasms | 2 | 2017 | 1951 | 0.120 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2015 | 49 | 0.120 |
Why?
|
| Aminoglycosides | 1 | 2015 | 233 | 0.120 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2015 | 163 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2023 | 13377 | 0.110 |
Why?
|
| United States | 5 | 2023 | 15887 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 2347 | 0.110 |
Why?
|
| Triazoles | 1 | 2017 | 628 | 0.110 |
Why?
|
| Imidazoles | 1 | 2019 | 1059 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 790 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 916 | 0.100 |
Why?
|
| Catheterization, Central Venous | 2 | 2017 | 366 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 307 | 0.100 |
Why?
|
| Pyridines | 1 | 2018 | 1310 | 0.100 |
Why?
|
| Time Factors | 2 | 2024 | 13023 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 353 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2011 | 107 | 0.090 |
Why?
|
| Blood | 1 | 2010 | 172 | 0.090 |
Why?
|
| Culture Media | 1 | 2010 | 347 | 0.090 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2011 | 172 | 0.090 |
Why?
|
| Aged | 11 | 2024 | 73259 | 0.080 |
Why?
|
| Adolescent | 7 | 2023 | 32722 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2010 | 132 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 1387 | 0.070 |
Why?
|
| Retrospective Studies | 10 | 2024 | 39750 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 2281 | 0.070 |
Why?
|
| Texas | 4 | 2016 | 6440 | 0.070 |
Why?
|
| Amebiasis | 1 | 2005 | 14 | 0.070 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2005 | 18 | 0.070 |
Why?
|
| Bacteria | 1 | 2010 | 653 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 1737 | 0.060 |
Why?
|
| Disease Outbreaks | 2 | 2004 | 405 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3939 | 0.060 |
Why?
|
| Zoonoses | 1 | 2004 | 54 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 1 | 2004 | 127 | 0.060 |
Why?
|
| Hepatitis C Antibodies | 1 | 2024 | 49 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2004 | 185 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 2024 | 95 | 0.060 |
Why?
|
| Risk Factors | 4 | 2023 | 17867 | 0.060 |
Why?
|
| Basal Ganglia Diseases | 1 | 2003 | 32 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 4138 | 0.050 |
Why?
|
| Immunoassay | 1 | 2024 | 214 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 543 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2004 | 234 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 658 | 0.050 |
Why?
|
| Viremia | 1 | 2023 | 182 | 0.050 |
Why?
|
| Survivorship | 1 | 2023 | 116 | 0.050 |
Why?
|
| Phylogeny | 1 | 2004 | 867 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 252 | 0.050 |
Why?
|
| Encephalitis | 1 | 2003 | 154 | 0.050 |
Why?
|
| Young Adult | 5 | 2023 | 22180 | 0.050 |
Why?
|
| Lung Transplantation | 1 | 2005 | 383 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2019 | 9469 | 0.050 |
Why?
|
| Dentists | 1 | 2020 | 11 | 0.050 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 15 | 0.050 |
Why?
|
| Povidone-Iodine | 1 | 2020 | 17 | 0.040 |
Why?
|
| Movement Disorders | 1 | 2003 | 236 | 0.040 |
Why?
|
| Mouthwashes | 1 | 2020 | 42 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 5182 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 62 | 0.040 |
Why?
|
| Prevalence | 2 | 2019 | 3406 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 772 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2020 | 111 | 0.040 |
Why?
|
| Cross Infection | 1 | 2003 | 547 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 793 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 696 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 276 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 370 | 0.040 |
Why?
|
| Tablets | 1 | 2017 | 56 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2017 | 73 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 7262 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 31000 | 0.040 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2017 | 41 | 0.040 |
Why?
|
| Receptors, Antigen | 1 | 2017 | 68 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 6688 | 0.040 |
Why?
|
| Hypertension | 2 | 1997 | 1594 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 2571 | 0.040 |
Why?
|
| Tertiary Healthcare | 1 | 2016 | 46 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2016 | 6231 | 0.030 |
Why?
|
| Fatigue | 1 | 2023 | 1278 | 0.030 |
Why?
|
| Angiotensinogen | 1 | 1996 | 23 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 248 | 0.030 |
Why?
|
| Gene Targeting | 1 | 1997 | 315 | 0.030 |
Why?
|
| Baroreflex | 1 | 1996 | 11 | 0.030 |
Why?
|
| Pressoreceptors | 1 | 1996 | 22 | 0.030 |
Why?
|
| Gram-Positive Cocci | 1 | 2015 | 10 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2024 | 973 | 0.030 |
Why?
|
| Renin | 1 | 1996 | 98 | 0.030 |
Why?
|
| Communication | 1 | 2022 | 854 | 0.030 |
Why?
|
| Galactose | 1 | 2015 | 79 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 1997 | 237 | 0.030 |
Why?
|
| Age Factors | 1 | 2004 | 5487 | 0.030 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 381 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 16212 | 0.030 |
Why?
|
| Aspergillus | 1 | 2015 | 151 | 0.030 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2014 | 19 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 4266 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 2159 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2014 | 55 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 74 | 0.030 |
Why?
|
| Incidence | 1 | 2024 | 5825 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 729 | 0.030 |
Why?
|
| Vancomycin | 1 | 2015 | 290 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 1613 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 6204 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 1997 | 4234 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2015 | 9303 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 3297 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Bacterial Load | 1 | 2011 | 45 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 1820 | 0.020 |
Why?
|
| Infant | 3 | 2012 | 13970 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 160 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2012 | 17041 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2005 | 5674 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 312 | 0.020 |
Why?
|
| Vancomycin Resistance | 1 | 2010 | 60 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2011 | 189 | 0.020 |
Why?
|
| Coinfection | 1 | 2011 | 202 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2856 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 3500 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 383 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 214 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2010 | 213 | 0.020 |
Why?
|
| Animals | 5 | 2005 | 62186 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 758 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2010 | 269 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 719 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 4870 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 290 | 0.020 |
Why?
|
| Acanthamoeba | 1 | 2005 | 17 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 3921 | 0.020 |
Why?
|
| Child | 3 | 2012 | 30549 | 0.020 |
Why?
|
| Pneumonia | 1 | 2012 | 796 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 9046 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 10257 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2010 | 678 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 2005 | 235 | 0.010 |
Why?
|
| New York | 1 | 2004 | 103 | 0.010 |
Why?
|
| Biomarkers | 1 | 2015 | 5072 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2005 | 831 | 0.010 |
Why?
|
| Disease Vectors | 1 | 2003 | 27 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2017 | 3547 | 0.010 |
Why?
|
| North America | 1 | 2004 | 338 | 0.010 |
Why?
|
| Culicidae | 1 | 2003 | 68 | 0.010 |
Why?
|
| Virulence | 1 | 2004 | 352 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 4962 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 467 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 14006 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 7784 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8624 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 22495 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 4862 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 2166 | 0.010 |
Why?
|
| Research | 1 | 1997 | 430 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 705 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 804 | 0.010 |
Why?
|
| Heart Rate | 1 | 1996 | 755 | 0.010 |
Why?
|
| Mice | 2 | 1997 | 35624 | 0.000 |
Why?
|
| Pregnancy | 1 | 1997 | 8095 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1997 | 7383 | 0.000 |
Why?
|